Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

NCT00392496 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma

Interventions

DRUG: sunitinib malate

Sponsor

National Cancer Institute (NCI)